January 25, 2010 – Trials for a stent that attracts endothelial progenitor cells show positive results in ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
January 8, 2010 – Japanese regulatory officials this week cleared the XIENCE V Everolimus-Eluting Coronary Stent ...
January 07, 2010
January 5, 2010 – In vivo and in vitro data released yesterday shows a new bioresorbable stent platform allows for ...
January 05, 2010
January 4, 2010 – The first patient was enrolled the TAXUS Liberte arm of the Dual Anti-Platelet Therapy (DAPT) ...
January 04, 2010
Feature | Stephanie LaBelle, senior analyst, Millennium Research Group
In recent years, the U.S. cardiac device market has focused on dynamics in the drug-eluting stent (DES) segment – ...
November 18, 2009
Feature | Dave Fornell
Standard drug-eluting stent technology seemed to have taken a backseat at this year’s TCT as cardiologists look ...
November 17, 2009
November 17, 2009 – Following positive three-year data from the first 30 patients treated with a fully ...
November 17, 2009
November 10, 2009 – Clinically, stent fracture has been reported in 1-2 percent of patients after drug-eluting ...
November 10, 2009
November 3, 2009 – Boston Scientific Corp. yesterday said it received CE Mark for its PROMUS Element Everolimus ...
November 03, 2009
November 3, 2009 – Abbott yesterday said both the XIENCE PRIME Everolimus-Eluting Coronary Stent System and the ...
November 03, 2009
October 21, 2009 – Raydiance Corp., developer of the world’s first commercial-grade ultrafast laser, said today it ...
October 21, 2009October 14, 2009 – Medtronic Inc. yesterday initiated a feasibility study of an interventional treatment for ...
October 14, 2009
October 6, 2009 – The Harvard Clinical Research Institute (HCRI) said last week the first patients are enrolled ...
October 06, 2009
October 6, 2009 – Boston Scientific Corp. released data during TCT 2009 from the TAXUS ATLAS clinical program, a ...
October 06, 2009
October 5, 2009 – In a breakthrough development that could dramatically reduce the number of leg amputations and ...
October 10, 2011© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now